Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Update

Co-Diagnostics, Inc. (NASDAQ:CODX) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 208,700 shares, a decline of 7.8% from the October 15th total of 226,400 shares. Based on an average daily volume of 246,900 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 price objective on shares of Co-Diagnostics in a research note on Monday, November 11th.

Co-Diagnostics Stock Up 1.9 %

Shares of CODX stock opened at $1.08 on Tuesday. The firm has a market cap of $34.48 million, a price-to-earnings ratio of -0.78 and a beta of -0.84. Co-Diagnostics has a 52-week low of $1.00 and a 52-week high of $2.23. The company’s 50 day moving average is $1.23 and its 200 day moving average is $1.25.

Hedge Funds Weigh In On Co-Diagnostics

A hedge fund recently bought a new stake in Co-Diagnostics stock. Jane Street Group LLC acquired a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned approximately 0.14% of Co-Diagnostics as of its most recent SEC filing. Institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.